Literature DB >> 11556405

Human T-cell leukemia virus type-I (HTLV-I) tax is not the only one factor to enhance human immunodeficiency virus type-I (HIV-1) infection in culture-supernatants.

A Tempaku1, Y Maeda, W Song, S Harada.   

Abstract

It is hypothesized that supernatants from cell cultures contain several factors to modify the human immunodeficiency virus type-1 (HIV-1) infection. Single round infection with pseudotyped viruses with envelope from HIV-1, amphotropic murine leukemia virus (A-MLV) and vesicular stomatitis virus G-protein (VSV-G) carrying luciferase reporter gene detected that not only human T-cell leukemia/lymphoma virus type-I (HTLV-1) transformed cells but also HTLV-I-unrelated T-cells and BJA-B cells released factors enhancing the infection with all pseudotyped viruses in their culture-supernatants. No supernatants upregulated the level of transcription from transfected DNA probe. suggesting that the action of supernatants is different from that of tumor necrosis factor (TNF) and Tax of HTLV-I. These results indicated that factors not always related to HTLV-I were ubiquitously produced and promoted viral infections, probably due to non-specific enhancement of early phase of the infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11556405     DOI: 10.1023/a:1011139530768

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  38 in total

1.  Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma.

Authors:  J Menezes; W Leibold; G Klein; G Clements
Journal:  Biomedicine       Date:  1975-07

2.  An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection.

Authors:  G Klein; B Giovanella; A Westman; J S Stehlin; D Mumford
Journal:  Intervirology       Date:  1975       Impact factor: 1.763

3.  Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus.

Authors:  G Klein; L Dombos; B Gothoskar
Journal:  Int J Cancer       Date:  1972-07-15       Impact factor: 7.396

4.  Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines.

Authors:  E Klein; G Klein; J S Nadkarni; J J Nadkarni; H Wigzell; P Clifford
Journal:  Cancer Res       Date:  1968-07       Impact factor: 12.701

5.  Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids.

Authors:  R D Salter; D N Howell; P Cresswell
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

6.  Host cyclophilin A mediates HIV-1 attachment to target cells via heparans.

Authors:  A C Saphire; M D Bobardt; P A Gallay
Journal:  EMBO J       Date:  1999-12-01       Impact factor: 11.598

7.  Establishment and characterization of a human histiocytic lymphoma cell line (U-937).

Authors:  C Sundström; K Nilsson
Journal:  Int J Cancer       Date:  1976-05-15       Impact factor: 7.396

8.  The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity.

Authors:  A Trkola; C Gordon; J Matthews; E Maxwell; T Ketas; L Czaplewski; A E Proudfoot; J P Moore
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

9.  The phorbol ester TPA strongly inhibits HIV-1-induced syncytia formation but enhances virus production: possible involvement of protein kinase C pathway.

Authors:  I H Chowdhury; Y Koyanagi; S Kobayashi; Y Hamamoto; H Yoshiyama; T Yoshida; N Yamamoto
Journal:  Virology       Date:  1990-05       Impact factor: 3.616

10.  Tumour necrosis factors (alpha, beta) induced by HIV-1 in peripheral blood mononuclear cells potentiate virus replication.

Authors:  A Vyakarnam; J McKeating; A Meager; P C Beverley
Journal:  AIDS       Date:  1990-01       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.